French animal health firm Vetoquinol's Q3 sales rise on Essentials segment growth

Overview

• France animal health firm's Q3 sales rose 10.4% yr/yr, driven by Essentials segment growth

• Essentials segment sales grew 13.9% in Q3, outpacing overall company growth

• Q3 growth benefited from a favorable base effect and currency tailwinds

Outlook

• Company did not provide specific guidance for future quarters or full-year 2026 in the press release

Result Drivers

• ESSENTIALS SEGMENT - Essentials product sales grew faster than overall company sales, driving Q3 results

• CURRENCY IMPACT - Favorable currency movements, mainly in the US and Americas, contributed €1 mln to Q3 sales

• PRODUCT LINE SIMPLIFICATION - Simplification of complementary product lines reduced Q3 sales by €0.6 mln

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Vetoquinol SA is €86.00, about 7.8% above its October 27 closing price of €79.80

• The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 14 three months ago

Reuters Recommended Reads

• Oct 28 - Higher prices lift Danone third-quarter sales

• Oct 28 - France's Remy Cointreau H1 sales rise, helped by Cognac growth in Asia

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)